On the fly News and insights, exclusive to thefly.com

BNTX

BioNTech

$209.08 /

-8.9 (-4.08%)

, X

U.S. Steel

$25.95 /

-0.99 (-3.67%)

09:53
06/16/21
06/16
09:53
06/16/21
09:53

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BioNTech (BNTX) downgraded to Sell from Neutral at Redburn with analyst Simon Baker saying the share gains since the end of March factor in more than the increase in value implied by recent guidance upgrades and revenue expectations for its Covid-19 vaccine. 2. U.S. Steel (X) downgraded to Underweight from Neutral at JPMorgan with analyst Michael Glick saying he is taking a "barbell approach" to his ratings, and cites the stock's outperformance year-to-date, lower out-year free cash flow, and "clunkier" asset base relative to Cliffs for the downgrade. 3. Insight Enterprises (NSIT) downgraded to Neutral from Overweight at JPMorgan with analyst Paul Coster citing valuation for the downgrade with the shares up 40% year-to-date and 110% year-over-year. 4. Sage Therapeutics (SAGE) downgraded to Market Perform from Outperform at William Blair with analyst Tim Lugo saying the data from the WATERFALL study support registration, but show a marginal benefit for zuranolone at the 50 mg dose, which could limit the commercial opportunity for the product and will likely lead to payer pushback. 5. ResMed (RMD) downgraded to Underperform from Neutral at BofA with analyst Lyanne Harrison believing that the market has over-reacted on positive side to a competitor's product recall and cites valuation for the rating change with shares trading at an all-time high price. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

BNTX

BioNTech

$209.08 /

-8.9 (-4.08%)

X

U.S. Steel

$25.95 /

-0.99 (-3.67%)

NSIT

Insight Enterprises

$103.26 /

-3.28 (-3.08%)

SAGE

Sage Therapeutics

$57.61 /

-1.4 (-2.37%)

RMD

ResMed

$234.62 /

-1.715 (-0.73%)

  • 23

    Jun

  • 13

    Jul

  • 09

    Aug

  • 18

    Jun

  • 23

    Jul

  • 03

    Feb

BNTX BioNTech
$209.08 /

-8.9 (-4.08%)

06/16/21 Redburn
BioNTech downgraded to Sell from Neutral at Redburn
05/18/21
Fly Intel: Top five analyst initiations
05/18/21 Goldman Sachs
BioNTech initiated with a Neutral at Goldman Sachs
05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
X U.S. Steel
$25.95 /

-0.99 (-3.67%)

06/16/21 JPMorgan
U.S. Steel assumed with Underweight from Neutral at JPMorgan
06/10/21 GLJ Research
GLJ ups U.S. Steel target, says valuation 'materially below reality'
06/04/21
Fly Intel: Top five analyst upgrades
06/04/21 UBS
U.S. Steel upgraded to Neutral from Sell at UBS
NSIT Insight Enterprises
$103.26 /

-3.28 (-3.08%)

06/16/21 JPMorgan
Insight Enterprises downgraded to Neutral on valuation at JPMorgan
06/16/21 JPMorgan
Insight Enterprises downgraded to Neutral from Overweight at JPMorgan
05/07/21 Barrington
Insight Enterprises price target raised to $110 from $102 at Barrington
02/12/21 Barrington
Insight Enterprises price target raised to $102 from $72 at Barrington
SAGE Sage Therapeutics
$57.61 /

-1.4 (-2.37%)

06/16/21 Truist
Sage Therapeutics price target lowered to $60 from $70 at Truist
06/16/21 Stifel
Sage Therapeutics price target lowered to $95 from $121 at Stifel
06/16/21 William Blair
Sage Therapeutics downgraded to Market Perform from Outperform at William Blair
06/16/21 BMO Capital
Sage Therapeutics price target lowered to $73 from $87 at BMO Capital
RMD ResMed
$234.62 /

-1.715 (-0.73%)

06/16/21 BofA
ResMed downgraded to Underperform from Neutral at BofA
06/15/21 Oppenheimer
ResMed price target raised to $270 from $240 at Oppenheimer
06/09/21 CLSA
ResMed upgraded to Outperform from Sell at CLSA
05/21/21 JPMorgan
ResMed upgraded to Overweight from Neutral at JPMorgan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.